Literature DB >> 3011884

Effects of danazol on steroidogenesis and gonadotropic responsiveness in isolated human preovulatory follicular cells.

J H Olsson, B Dennefors, L Nilsson.   

Abstract

In order to investigate the influence of danazol on steroidogenesis and gonadotropic responsiveness of human follicular cells, granulosa and thecal cells of preovulatory follicles were isolated and separately incubated for short term periods. Human chorionic gonadotropin (hCG) (100 IU/ml), FSH (0.5 IU/ml) and danazol (10 micrograms/ml) alone or in combination were added to the incubation medium. Following incubation the cellular cyclic adenosine 3'5' monophosphate (cAMP) levels and the medium content of progesterone (P), androstenedione (A) and 17 beta-estradiol (E2) were determined. All follicles included in the study were classified as nonatretic and well developed, i.e. less than 3 days before ovulation. Human chorionic gonadotropin caused an increase in cAMP formation in both cell-types and this effect was significantly counteracted by danazol in vitro. In granulosa cells danazol tended to counteract a stimulatory effect of FSH on cAMP formation. No significant influence of danazol was found on the basal steroid formation of both cell types during short term incubation. On the other hand, danazol significantly counteracted the FSH stimulated P formation of the granulosa cells and the hCG stimulated A and E2 formation of the thecal cells. It is concluded that danazol inhibits gonadotropin-stimulated steroidogenesis locally in the human follicular cells and that this effect of danazol is mediated via the cyclic AMP system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011884     DOI: 10.1007/BF03348079

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Hormonal changes associated with Danazol therapy.

Authors:  G P Wood; C H Wu; G L Flickinger; G Mikhail
Journal:  Obstet Gynecol       Date:  1975-03       Impact factor: 7.661

2.  The use of danazol in the management of endometriosis.

Authors:  M D Young; W P Blackmore
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

3.  The effect of danazol in the treatment of chronic cystic mastitis.

Authors:  N H Lauersen; K H Wilson
Journal:  Obstet Gynecol       Date:  1976-07       Impact factor: 7.661

4.  Contraceptive properties of Danazol.

Authors:  M L Colle; R B Greenblatt
Journal:  J Reprod Med       Date:  1976-08       Impact factor: 0.142

5.  Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries.

Authors:  G F Erickson; A J Hsueh; M E Quigley; R W Rebar; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1979-10       Impact factor: 5.958

6.  The effect of danazol in sexual precocity.

Authors:  P A Lee; R G Thompson; C J Migeon; R M Blizzard
Journal:  Johns Hopkins Med J       Date:  1975-12

7.  Mechanism of induction of luteal phase defects by danazol.

Authors:  R H Asch; E O Fernandez; T M Siler-Khodr; A Bartke; C J Pauerstein
Journal:  Am J Obstet Gynecol       Date:  1980-04-01       Impact factor: 8.661

8.  Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation.

Authors:  M Menon; S Azhar; K M Menon
Journal:  Am J Obstet Gynecol       Date:  1980-02-15       Impact factor: 8.661

9.  Danazol inhibits human adrenal 21-and 11 beta-hydroxylation in vitro.

Authors:  R L Barbieri; R Osathanondh; J A Canick; R J Stillman; K J Ryan
Journal:  Steroids       Date:  1980-03       Impact factor: 2.668

10.  Evidence of a possible direct action of Danazol on the human ovary.

Authors:  A Milwidsky; N F Besch; P K Besch; R H Kaufman
Journal:  Acta Obstet Gynecol Scand       Date:  1983       Impact factor: 3.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.